Home > News > BioAlliance Pharma Announces Preliminary Results
June 30th, 2006
BioAlliance Pharma Announces Preliminary Results
Abstract:
BioAlliance Pharma SA (Paris:BIO) announced today the presentation of preliminary results from its Doxorubicin Transdrug(R) Phase I/II clinical trial for primary liver cancer. "These results are also extremely positive because of their encouraging implications for the future application of our Transdrug(R) nanotechnology platform."
Source:
businesswire
Related News Press |
Possible Futures
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
With VECSELs towards the quantum internet Fraunhofer: IAF achieves record output power with VECSEL for quantum frequency converters April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||